An increasing number of life sciences companies of all sizes are considering intellectual property migration as an opportunity to achieve legal, tax and operational efficiencies. When considering the adoption of this strategy, it is critically important for executives to understand the requirements and benefits associated with such a reorganization of an IP portfolio.
During this webinar, WilmerHale Partners Rich Andersen, Steve Barrett and Stuart Falber discuss: the criteria to determine whether a company is a candidate; the advantages and disadvantages of IP migration; the process for companies to reorganize their IP portfolio; and representative structures as they pertain to life sciences companies.
